Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 3/2009

01.03.2009 | Review Article

Complications of traditional Chinese/herbal medicines (TCM)—a guide for perplexed oncologists and other cancer caregivers

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Cancer patients often seek complementary or alternative medicines to supplement or replace treatments prescribed by licensed medical practitioners. Traditional Chinese/herbal medicine (TCM) is a popular complementary intervention among cancer patients of Asian ethnicity, many of whom take it during their conventional treatment. Few of these patients inform their doctors, however, creating a risk of unexpected sequelae arising from either pharmacologic toxicity, unsuitable dosing, interactions with anti-cancer drugs or other medications, adulteration, or idiosyncratic reactions. If unrecognized, these problems may be misattributed to conventional treatment toxicity or disease progression, and remedial action may be inappropriate or delayed.

Goals of work

The purpose of this review is to help oncologists recognize the common presentations of TCM-related problems in cancer patients—such as abnormal liver function tests, unexpectedly severe myelosuppression, hemostatic defects, renal functional impairment, or suspected drug interactions—and to teach strategies by which these problems can be anticipated, prevented, or managed.

Conclusion

Through sensitive understanding of the reasons favoring TCM usage, oncologists can gain the trust and respect of their TCM-using patients while ensuring the safety and efficacy of conventional anticancer treatments.
Fußnoten
1
Now no longer marketed.
 
Literatur
1.
Agbabiaka TB, Savovic J, Ernst E (2008) Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 31:21–37PubMed
2.
Aithal GP (2005) When is a herb a drug. Eur J Gastroenterol Hepatol 17:391–393PubMed
3.
Ashby MA, Kissane DW, Beadle GF, Rodger A (1996) Psychosocial support, treatment of metastatic disease and palliative care. Med J Aust 164:43–49PubMed
4.
Bajwa RP, Cant AJ, Abinun M, Flood TJ, Hodges S, Hale JP, Skinner R (2003) Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment. Bone Marrow Transplant 31:591–597PubMed
5.
Batey RG, Bensoussan A, Fan YY, Bollipo S, Hossain MA (1998) Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 13:244–247PubMedCrossRef
6.
Boon HS, Olatunde F, Zick SM (2007) Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 7:4PubMed
7.
Brazier NC, Levine MA (2003) Drug–herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 10:163–169PubMed
8.
Canter PH, Ernst E (2004) Herbal supplement use by persons aged over 50 years in Britain: frequently used herbs, concomitant use of herbs, nutritional supplements and prescription drugs, rate of informing doctors and potential for negative interactions. Drugs Aging 21:597–605PubMed
9.
Cassileth BR, Deng G (2004) Complementary and alternative therapies for cancer. Oncologist 9:80–89PubMed
10.
Chalandon Y, Roosnek E, Mermillod B, Newton A, Ozsahin H, Wacker P, Helg C, Chapuis B (2004) Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 10:347–354PubMed
11.
Chamberlain JJ, Abolnik IZ (1997) Pulmonary edema following a licorice binge. West J Med 167:184–185PubMed
12.
Chen M, Su M, Zhao L, Jiang J, Liu P, Cheng J, Lai Y, Liu Y, Jia W (2006) Metabonomic study of aristolochic acid-induced nephrotoxicity in rats. J Proteome Res 5:995–1002PubMed
13.
Chiu SW, Wang ZM, Leung TM, Moore D (2000) Nutritional value of ganoderma extract and assessment of its genotoxicity and antigenotoxicity using comet assays of mouse lymphocytes. Food Chem Toxicol 38:173–178PubMed
14.
Chrystal K, Allan S, Forgeson G, Isaacs R (2003) The use of complementary/alternative medicine by cancer patients in a New Zealand regional cancer treatment centre. N Z Med J 116:U296PubMed
15.
Chu DT, Wong WL, Mavligit GM (1988) Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Clin Lab Immunol 25:125–129PubMed
16.
Correa-Velez I, Clavarino A, Eastwood H (2005) Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis. J Palliat Med 8:953–961PubMed
17.
Cosyns JP, Jadoul M, Squifflet JP, De Plaen JF, Ferluga D, van Ypersele de Strihou C (1994) Chinese herbs nephropathy: a clue to Balkan endemic nephropathy. Kidney Int 45:1680–1688PubMed
18.
Dai N, Yu YC, Ren TH, Wu JG, Jiang Y, Shen LG, Zhang J (2007) Gynura root induces hepatic veno-occlusive disease: a case report and review of the literature. World J Gastroenterol 13:1628–1631PubMed
19.
Deng G, Cassileth BR, Yeung KS (2004) Complementary therapies for cancer-related symptoms. J Support Oncol 2:419–426 discussion 427–419PubMed
20.
Donovan JL, DeVane CL, Chavin KD, Taylor RM, Markowitz JS (2003) Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos 31:519–522PubMed
21.
22.
Eastwood MA, Brydon WG, Anderson DM (1984) The effects of dietary gum tragacanth in man. Toxicol Lett 21:73–81PubMed
23.
Ernst E (2000) The role of complementary and alternative medicine in cancer. Lancet Oncol 1:176–180PubMed
24.
Ernst E (2004) Risks of herbal medicinal products. Pharmacoepidemiol Drug Saf 13:767–771PubMed
25.
Farese RV Jr., Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R (1991) Licorice-induced hypermineralocorticoidism. N Engl J Med 325:1223–1227PubMed
26.
Feldmeyer N, Schmeiser HH, Muehlbauer KR, Belharazem D, Knyazev Y, Nedelko T, Hollstein M (2006) Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat Res 608:163–168PubMed
27.
Fessenden JM, Wittenborn W, Clarke L (2001) Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg 67:33–35PubMed
28.
Frenkel M, Ben-Arye E, Baldwin CD, Sierpina V (2005) Approach to communicating with patients about the use of nutritional supplements in cancer care. South Med J 98:289–294PubMed
29.
Fu PP, Xia Q, Lin G, Chou MW (2004) Pyrrolizidine alkaloids—genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 36:1–55PubMed
30.
Gerber B, Scholz C, Reimer T, Briese V, Janni W (2006) Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. Breast Cancer Res Treat 95:199–209PubMed
31.
Goel A, Boland CR, Chauhan DP (2001) Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 172:111–118PubMed
32.
Greenspan EM (1983) Ginseng and vaginal bleeding. Jama 249:2018PubMed
33.
Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelic M, Jelakovic B (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A 104:12129–12134PubMed
34.
Guh JY, Chen HC, Tsai JF, Chuang LY (2007) Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. Am J Kidney Dis 49:626–633PubMed
35.
Guo R, Canter PH, Ernst E (2007) A systematic review of randomised clinical trials of individualised herbal medicine in any indication. Postgrad Med J 83:633–637PubMed
36.
Hammond TG, Whitworth JA (1981) Adverse reactions to ginseng. Med J Aust 1:492PubMed
37.
Harada T, Ohtaki E, Misu K, Sumiyoshi T, Hosoda S (2002) Congestive heart failure caused by digitalis toxicity in an elderly man taking a licorice-containing Chinese herbal laxative. Cardiology 98:218PubMed
38.
Hlubocky FJ, Ratain MJ, Wen M, Daugherty CK (2007) Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol 25:548–554PubMed
39.
Holmes TH, Rahe RH (1967) The social readjustment rating scale. J Psychosom Res 11:213–218PubMed
40.
Hsieh TC, Lu X, Chea J, Wu JM (2002) Prevention and management of prostate cancer using PC-SPES: a scientific perspective. J Nutr 132:3513S–3517SPubMed
41.
Huxtable RJ (1990) Activation and pulmonary toxicity of pyrrolizidine alkaloids. Pharmacol Ther 47:371–389PubMed
42.
Ishizaki T, Sasaki F, Ameshima S, Shiozaki K, Takahashi H, Abe Y, Ito S, Kuriyama M, Nakai T, Kitagawa M (1996) Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J 9:2691–2696PubMed
43.
Janetzky K, Morreale AP (1997) Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 54:692–693PubMed
44.
Kimby CK, Launso L, Henningsen I, Langgaard H (2003) Choice of unconventional treatment by patients with cancer. J Altern Complement Med 9:549–561PubMed
45.
Kumar NB, Allen K, Bell H (2005) Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control 12:149–157PubMed
46.
Kwok Y, Ng KF, Li CC, Lam CC, Man RY (2005) A prospective, randomized, double-blind, placebo-controlled study of the platelet and global hemostatic effects of Ganoderma lucidum (Ling-Zhi) in healthy volunteers. Anesth Analg 101:423–426 table of contentsPubMed
47.
Lam AY, Elmer GW, Mohutsky MA (2001) Possible interaction between warfarin and Lycium barbarum L. Ann Pharmacother 35:1199–1201PubMed
48.
Li M, Handa S, Ikeda Y, Goto S (2001) Specific inhibiting characteristics of tetramethylpyrazine, one of the active ingredients of the Chinese herbal medicine ‘Chuanxiong,’ on platelet thrombus formation under high shear rates. Thromb Res 104:15–28PubMed
49.
Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD (2001) Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358:1515–1516PubMed
50.
Lord GM, Tagore R, Cook T, Gower P, Pusey CD (1999) Nephropathy caused by Chinese herbs in the UK. Lancet 354:481–482PubMed
51.
Manusirivithaya S, Sripramote M, Tangjitgamol S, Sheanakul C, Leelahakorn S, Thavaramara T, Tangcharoenpanich K (2004) Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer 14:1063–1069PubMed
52.
Martena MJ, van der Wielen JC, van de Laak LF, Konings EJ, de Groot HN, Rietjens IM (2007) Enforcement of the ban on aristolochic acids in Chinese traditional herbal preparations on the Dutch market. Anal Bioanal Chem 389:263–275PubMed
53.
Martinez-Mir I, Rubio E, Morales-Olivas FJ, Palop-Larrea V (2004) Transient ischemic attack secondary to hypertensive crisis related to Panax ginseng. Ann Pharmacother 38:1970PubMed
54.
McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM Jr. (2006) Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 24:419–430PubMed
55.
McCune JS, Hatfield AJ, Blackburn AA, Leith PO, Livingston RB, Ellis GK (2004) Potential of chemotherapy–herb interactions in adult cancer patients. Support Care Cancer 12:454–462PubMed
56.
McRae S (1996) Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. Cmaj 155:293–295PubMed
57.
Meijerman I, Beijnen JH, Schellens JH (2006) Herb–drug interactions in oncology: focus on mechanisms of induction. Oncologist 11:742–752PubMed
58.
Miller LG (1998) Herbal medicinals: selected clinical considerations focusing on known or potential drug–herb interactions. Arch Intern Med 158:2200–2211PubMed
59.
Mishra B, Priyadarsini KI, Bhide MK, Kadam RM, Mohan H (2004) Reactions of superoxide radicals with curcumin: probable mechanisms by optical spectroscopy and EPR. Free Radic Res 38:355–362PubMed
60.
Mok TS, Yeo W, Johnson PJ, Hui P, Ho WM, Lam KC, Xu M, Chak K, Chan A, Wong H, Mo F, Zee B (2007) A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol 18:768–774PubMed
61.
Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–663PubMed
62.
Morales A, Pujari B (1975) The choice of estrogen preparations in the treatment of prostatic cancer. Can Med Assoc J 113:865–867PubMed
63.
Nahleh Z, Tabbara IA (2003) Complementary and alternative medicine in breast cancer patients. Palliat Support Care 1:267–273PubMedCrossRef
64.
Nielsen I, Pedersen RS (1984) Life-threatening hypokalaemia caused by liquorice ingestion. Lancet 1:1305PubMed
65.
Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342:1686–1692PubMed
66.
Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ (2004) Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 22:3705–3712PubMed
67.
Ono K, Nakane H, Meng ZM, Ose Y, Sakai Y, Mizuno M (1989) Differential inhibitory effects of various herb extracts on the activities of reverse transcriptase and various deoxyribonucleic acid (DNA) polymerases. Chem Pharm Bull (Tokyo) 37:1810–1812
68.
Page RL 2nd, Lawrence JD (1999) Potentiation of warfarin by dong quai. Pharmacotherapy 19:870–876PubMed
69.
Pak E, Esrason KT, Wu VH (2004) Hepatotoxicity of herbal remedies: an emerging dilemma. Prog Transplant 14:91–96PubMed
70.
Palop-Larrea V, Gonzalvez-Perales JL, Catalan-Oliver C, Belenguer-Varea A, Martinez-Mir I (2000) Metrorrhagia and ginseng. Ann Pharmacother 34:1347–1348PubMed
71.
Pan KY, Lin JL, Chen JS (2001) Severe reversible bone marrow suppression induced by Selaginella doederleinii. J Toxicol Clin Toxicol 39:637–639PubMed
72.
Piper JT, Singhal SS, Salameh MS, Torman RT, Awasthi YC, Awasthi S (1998) Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int J Biochem Cell Biol 30:445–456PubMed
73.
Pittler MH, Ernst E (2003) Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 18:451–471PubMed
74.
Rasyid A, Lelo A (1999) The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 13:245–249PubMed
75.
Richardson MA (2001) Biopharmacologic and herbal therapies for cancer: research update from NCCAM. J Nutr 131:3037S–3040SPubMed
76.
Roberts CS, Baker F, Hann D, Runfola J, Witt C, McDonald J, Livingston ML, Ruiterman J, Ampela R, Kaw OC, Blanchard C (2005) Patient–physician communication regarding use of complementary therapies during cancer treatment. J Psychosoc Oncol 23:35–60PubMed
77.
Ryu SJ, Chien YY (1995) Ginseng-associated cerebral arteritis. Neurology 45:829–830PubMed
78.
Saw JT, Bahari MB, Ang HH, Lim YH (2006) Potential drug–herb interaction with antiplatelet/anticoagulant drugs. Complement Ther Clin Pract 12:236–241PubMed
79.
Seguro AC, Campos SB (2002) Diuretic effect of sodium artesunate in patients with malaria. Am J Trop Med Hyg 67:473–474PubMed
80.
Senthilnathan P, Padmavathi R, Banu SM, Sakthisekaran D (2006) Enhancement of antitumor effect of paclitaxel in combination with immunomodulatory Withania somnifera on benzo(a)pyrene induced experimental lung cancer. Chem Biol Interact 159:180–185PubMed
81.
Shah BH, Nawaz Z, Pertani SA, Roomi A, Mahmood H, Saeed SA, Gilani AH (1999) Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem Pharmacol 58:1167–1172PubMed
82.
Shah RG, Netrawali MS (1988) Evaluation of mutagenic activity of turmeric extract containing curcumin, before and after activation with mammalian cecal microbial extract of liver microsomal fraction, in the Ames Salmonella test. Bull Environ Contam Toxicol 40:350–357PubMed
83.
Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP (2001) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7:1894–1900PubMed
84.
Sheu JR, Kan YC, Hung WC, Lin CH, Yen MH (2000) The antiplatelet activity of tetramethylpyrazine is mediated through activation of NO synthase. Life Sci 67:937–947PubMed
85.
Shu X, McCulloch M, Xiao H, Broffman M, Gao J (2005) Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Integr Cancer Ther 4:219–229PubMed
86.
Shumay DM, Maskarinec G, Kakai H, Gotay CC (2001) Why some cancer patients choose complementary and alternative medicine instead of conventional treatment. J Fam Pract 50:1067PubMed
87.
Singh H, Maskarinec G, Shumay DM (2005) Understanding the motivation for conventional and complementary/alternative medicine use among men with prostate cancer. Integr Cancer Ther 4:187–194PubMed
88.
Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM (2000) Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18:3595–3603PubMed
89.
Stiborova M, Frei E, Sopko B, Wiessler M, Schmeiser HH (2002) Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23:617–625PubMed
90.
Stickel F, Schuppan D (2007) Herbal medicine in the treatment of liver diseases. Dig Liver Dis 39:293–304PubMed
91.
Stickel F, Seitz HK (2000) The efficacy and safety of comfrey. Public Health Nutr 3:501–508PubMed
92.
Sun Y (1988) The role of traditional Chinese medicine in supportive care of cancer patients. Recent Results Cancer Res 108:327–334PubMed
93.
Tagliaferri M, Cohen I, Tripathy D (2001) Complementary and alternative medicine in early-stage breast cancer. Semin Oncol 28:121–134PubMed
94.
Tatsumura Y, Maskarinec G, Shumay DM, Kakai H (2003) Religious and spiritual resources, CAM, and conventional treatment in the lives of cancer patients. Altern Ther Health Med 9:64–71PubMed
95.
To KK, Au-Yeung SC, Ho YP (2006) Differential nephrotoxicity of cisplatin and a novel series of traditional Chinese medicine–platinum anticancer agents correlates with their chemical reactivity towards sulfur-containing nucleophiles. Anticancer Drugs 17:673–683PubMed
96.
Toovey S, Jamieson A (2004) Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 98:261–267 discussion 268–269PubMed
97.
Tripathi YB, Tripathi P, Arjmandi BH (2005) Nutraceuticals and cancer management. Front Biosci 10:1607–1618PubMed
98.
Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R et al (1993) Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341:387–391PubMed
99.
Vanherweghem LJ (1998) Misuse of herbal remedies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). J Altern Complement Med 4:9–13PubMed
100.
Wachtel-Galor S, Tomlinson B, Benzie IF (2004) Ganoderma lucidum (“Lingzhi”), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Br J Nutr 91:263–269PubMed
101.
Walker BR, Edwards CR (1994) Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am 23:359–377PubMed
102.
Wanachiwanawin D, Piankijagum A, Chaiprasert A, Lertlaituan P, Tungtrongchitr A, Chinabutr P (2006) Ganoderma lucidum: a cause of pseudoparasitosis. Southeast Asian J Trop Med Public Health 37:1099–1102PubMed
103.
Wang YP, Fu PP, Chou MW (2005) Metabolic activation of the tumorigenic pyrrolizidine alkaloid, retrorsine, leading to DNA adduct formation in vivo. Int J Environ Res Public Health 2:74–79PubMed
104.
Wang ZY, Nixon DW (2001) Licorice and cancer. Nutr Cancer 39:1–11PubMed
105.
White M, Verhoef M (2006) Cancer as part of the journey: the role of spirituality in the decision to decline conventional prostate cancer treatment and to use complementary and alternative medicine. Integr Cancer Ther 5:117–122PubMed
106.
Willetts KE, Ekangaki A, Eden JA (2003) Effect of a ginger extract on pregnancy-induced nausea: a randomised controlled trial. Aust N Z J Obstet Gynaecol 43:139–144PubMed
107.
Wu K, Jiang L, Cao J, Yang G, Geng C, Zhong L (2007) Genotoxic effect and nitrative DNA damage in HepG2 cells exposed to aristolochic acid. Mutat Res 630:97–102PubMed
108.
Wu ML, Deng JF, Wu JC, Fan FS, Yang CF (2004) Severe bone marrow depression induced by an anticancer herb Cantharanthus roseus. J Toxicol Clin Toxicol 42:667–671PubMed
109.
Yang HY, Lin JL, Chen KH, Yu CC, Hsu PY, Lin CL (2006) Aristolochic acid-related nephropathy associated with the popular Chinese herb Xi Xin. J Nephrol 19:111–114PubMed
110.
Yang L, Li X, Wang H (2007) Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid-induced acute tubular necrosis. Nephrol Dial Transplant 22:445–456PubMed
111.
Yates JS, Mustian KM, Morrow GR, Gillies LJ, Padmanaban D, Atkins JN, Issell B, Kirshner JJ, Colman LK (2005) Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13:806–811PubMed
112.
Yuen MF, Tam S, Fung J, Wong DK, Wong BC, Lai CL (2006) Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. Aliment Pharmacol Ther 24:1179–1186PubMed
113.
Zhou SF, Xue CC, Yu XQ, Wang G (2007) Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab 8:526–553PubMed
Metadaten
Titel
Complications of traditional Chinese/herbal medicines (TCM)—a guide for perplexed oncologists and other cancer caregivers
Publikationsdatum
01.03.2009
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2009
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0526-x

Weitere Artikel der Ausgabe 3/2009

Supportive Care in Cancer 3/2009 Zur Ausgabe

Original Article

Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence

Original Article

The Efficacy of prophylactic Shakuyaku-Kanzo-to for myalgia and arthralgia following Carboplatin and Paclitaxel combination chemotherapy for non-small cell lung cancer

Original Article

Age-specific correlates of quality of life in Chinese women with cervical cancer

Original Article

Vancomycin flush as antibiotic prophylaxis for early catheter-related infections: a cost-effectiveness analysis

Supportive Care International

Perceived importance of evidence-based psychosocial clinical guidelines for Hong Kong Chinese women with breast cancer: opinions of patients and health care providers

Original Article

Life goals and purpose in life in cancer patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise